
NeuroCRU
@neurocru
Clinical Research Unit (CRU) at The Neuro - a leading centre affiliated with McGill | Unité de recherche clinique du Neuro, un centre de pointe affilié à McGill
ID: 1245768416369291264
http://CRU.McGill.Ca 02-04-2020 17:42:21
257 Tweet
352 Followers
257 Following



De grands changements en vue pour les québécois atteints de la #dystrophiemyotonique. De nouveaux #essaiscliniques testent des traitements prometteurs ciblant le problème génétique de la #DM1. Entrevue: cru.mcgill.ca/fr/dystrophie-…. Essais: 514-398-5500; [email protected].


🧬1st patient ever for a trial on #priondisease at NeuroCRU received their 1st dose yesterday. #RNA treatment studied hopes to slow progression of rare but devastating genetic conditions like #CJD and #GSS. Interview: cru.mcgill.ca/creutzfeldt-ja…. For trials: [email protected]








CRU exec director Ziv Gan-Or was in Vienna for #RARE2025 to discuss his lab’s work understanding #GBA1, the genetic mutation behind a rare subtype of #Parkinsons. The CRU works to offer the most advanced investigational therapies for rare diseases, including RNA and gene therapies



NeuroCRU exec dir Ziv Gan-Or gave a keynote talk at @SleepEurope virtual congress discussing his lab’s work on the genetics of #RBD, allowing researchers to find #genetic targets like #GBA1 for #drugdevelopment and to identify patients who'll progress rapidly in clinical trials.




🔬Plusieurs nouveaux essais cliniques visant à ralentir la progression de la #SP débuteront bientôt au NeuroCRU. 🩺Several new studies aiming to slow the progression of #MS starting soon at Neuro CRU. 📩Info: cru.mcgill.ca/ms or [email protected].

Exec dir Ziv Gan-Or spoke at The International RBD Study Group's annual mtg. He discussed the importance of using human-derived data + models in identifying, testing new treatments for #RBD, #Parkinsons, and shared his lab’s latest findings of potential genes + biological pathways involved in RBD

